Abexxa Biologics is changing how we treat cancer. Using immunotherapy, Jon Weidanz is treating cancer through novel biotechnology that targets cancer cells and boosts the immune systems of patients. Jon and Debra Weidanz are the co-founders of the biotech company Abexxa Biologics, which was acquired by Boehringer Ingelheim (BI) in 2021. Jon shares how he raised capital from BI venture funds, how Abexxa won their Golden Ticket competition, and how they went from lab discovery to acquisition in just a few years.
Sign Up 
